Founder urgency
Parent-founders build companies with one purpose: to save their child.
For investors & pharma partners
Back the most determinedfounders in drug development.
Capital, infrastructure and regulatory expertise for family-founded biotechs — anchored in the FDA Rare Pediatric Disease PRV program.
The PRV model
A faster review — or a sellable asset.
On approval, a qualifying sponsor receives a transferable voucher for priority review of a future product.
The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program rewards sponsors who win approval for a drug or biologic that treats a rare pediatric disease. At approval, the sponsor receives a transferable voucher for Priority Review of a future product (about 6 months, vs. the standard 10), or it can sell the voucher to another company, historically a source of non-dilutive capital. The incentive offsets the cost and risk of serving very small patient populations, where traditional commercial incentives are limited.
- Who qualifiesA new drug or biologic (a new NDA or BLA with a new active ingredient) for a serious or life-threatening disease that mainly affects patients from birth to age 18.
- The rarity barFewer than 200,000 people affected in the U.S., or no reasonable expectation of recovering development costs.
- Awarded at approvalBacked by clinically meaningful pediatric data, the voucher is issued when the product is approved and announced in the Federal Register.
- Program statusActive again following reauthorization, with multiple vouchers awarded and sold across 2025 and 2026.
PRV market · Oct 2026
$210M
most recent disclosed sale, down 2% vs. the prior sale
$180–220M
range of disclosed sale prices in 2026
125
vouchers issued across all FDA PRV programs; 75 redeemed
Source: PRV Watch (prvwatch.com), as of Oct 2026. Disclosed sales across all FDA PRV programs. For information only; not investment advice.
PRVs sold over time (USD)
69 disclosed sales · 2014–2026Why FAMCOs
The most motivated operators in biopharma.
Lean by design
Family-led programs move faster, at a fraction of the cost.
Designation-first diligence
RPDD early, plus M&A-style diligence including freedom-to-operate.
Aligned upside
PRV proceeds are shared between family-founders and 1000 Cures.
Program durability
Why 2029 is a low risk.
Rare Pediatric Disease PRVs can currently be awarded on approvals through September 30, 2029. The program’s track record makes that date a checkpoint, not a cliff.
Reauthorized again and again
Created in 2012 and extended in 2016, 2020 and February 2026, with broad bipartisan support. Past lapses were resolved quickly.
Only the award has a deadline
The 2029 date applies to vouchers awarded at approval. Rare Pediatric Disease Designations continue independently, so designated programs keep multi-year runways.
Permanence is on the table
The FDA’s 2027 budget proposal calls for permanent authorization, citing treatments for 47 rare pediatric diseases since 2012. In September 2026, the bipartisan Priority for Pediatric Cures Act (H.R.10359) was introduced to make the program permanent.
Reauthorization timeline
- CreatedThe Rare Pediatric Disease PRV program is established.
- ExtendedCongress extends the program.
- ExtendedCongress extends the program again.
- ReauthorizedConsolidated Appropriations Act of 2026 (Mikaela Naylon Give Kids a Chance Act), signed Feb 3.
- Permanence billH.R.10359, the Priority for Pediatric Cures Act, introduced Sept 14 to make the program permanent. Pending in committee.
- Next checkpointCurrent sunset for vouchers awarded at approval.
Sources: 1000 Cures investor memo (June 2026) and launch article; Consolidated Appropriations Act of 2026, signed Feb 3, 2026. H.R.10359 status per Congress.gov, as of Oct 2026. Views on future reauthorization are 1000 Cures’ opinion, not a guarantee of future legislation. Not investment advice.
Proof point · Maggie’s Pearl
3 yrs
screen to pivotal trial (industry: 7)
$5M
total cost (industry: $166M)
Lean, family-led development works.
Formed in 2020 as a joint venture of Perlara, the family-founded Maggie’s Cure and Mayo Clinic, Maggie’s Pearl is developing the first platform therapy for congenital disorders of glycosylation (CDG).
- IndicationPMM2-CDG, a rare genetic disorder known to affect roughly 1,000 people worldwide.
- ApproachPerlara’s drug-repurposing screens identified epalrestat, used for decades in Asia to treat diabetic nerve damage.
- MilestoneAn FDA-cleared Phase III trial at Mayo Clinic for up to 40 children, ages 2–17, is fully enrolled.
Portfolio
Over 60 programs screened.
Program 01
GMPPA-CDG · Family-founded
Announcing Q4 2026Pipeline: Discovery, Rare Pediatric Disease Designation complete. Current stage: N-of-1 (IND Application), underway. Next: NDA-enabling studies (Phase 1/2/3).
Program 02
Leigh syndrome · Family-founded
Announcing Q4 2026Pipeline: Discovery, Rare Pediatric Disease Designation complete. Current stage: N-of-1 (IND Application), underway. Next: NDA-enabling studies (Phase 1/2/3).
More programs announced soon
PortfolioResources
Guides and news.
Plain-language explainers for parent-founders and partners.
Partner with us
Let’s build the next cure together.
Investors, pharma partners and rare disease organizations — we’d welcome a conversation.